Amgen Award For Science Teaching Excellence Honors Outstanding Teachers

[2013-06-19] - Award Demonstrates Amgen's Commitment to the Next Generation of Innovators and the Teachers who Inspire Them

FDA Approves Amgen's XGEVA® (denosumab) For The Treatment Of Giant Cell Tumor Of Bone

[2013-06-13] - XGEVA Becomes First FDA-Approved Treatment for This Rare Disease

Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting

[2013-06-12] -

Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer

[2013-06-12] - Study Meets Primary Endpoint of Progression-Free Survival

Amgen To Present At The Goldman Sachs 34th Annual Global Healthcare Conference

[2013-06-06] -

Amgen Presents Positive Results From Talimogene Laherparepvec Phase 3 Study In Patients With Metastatic Melanoma

[2013-06-01] -

Amgen And Astellas Announce Japan Alliance

[2013-05-29] - Innovative Joint Venture to Address Unmet Medical Needs of Patients in Japan

Amgen To Webcast Investor Meeting At Upcoming American Society Of Clinical Oncology Annual Meeting

[2013-05-29] -

Amgen to Present at the Deutsche Bank 38th Annual Healthcare Conference

[2013-05-23] -

Amgen Announces Voting Results of Annual Meeting of Stockholders

[2013-05-22] -

Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China

[2013-05-09] - Goal Is to Bring Amgen's Vectibix® (Panitumumab) to Chinese Patients

Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China

[2013-05-09] -

Amgen Announces Top-Line Results of Vectibix® (panitumumab) Phase 3 Head-to-Head Study Against Erbitux® (cetuximab) in Metastatic Colorectal Cancer

[2013-05-07] - Study Meets Primary Endpoint of Non-Inferiority in Monotherapy Setting

1 - 2
Most read: scientific news



Follow us...

google plus Facebook twitter Newsletter



Plan du site